Literature DB >> 11186131

Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

N Ariyoshi1, Y Takahashi, M Miyamoto, Y Umetsu, S Daigo, T Tateishi, S Kobayashi, Y Mizorogi, M A Loriot, I Stücker, P Beaune, M Kinoshita, T Kamataki.   

Abstract

During the course of investigating the frequency of a CYP2A6 whole deletion-type polymorphism (CYP2A6*4C) in Japanese, an unexpectedly large population of heterozygotes for CYP2A6*4C and the wild-type (CYP2A6*1A) was found. Cloning of a cDNA encoding CYP2A6 from the liver of individuals judged as heterozygotes for CYP2A6*4C and the CYP2A6*1A was carried out to identify the causal allele(s) responsible for a possible overestimation. A clone isolated from the liver cDNA library possessed 58 bp sequences in the 3'-untranslated region, which was replaced with the corresponding region of the CYP2A7 gene. The same gene conversion existed in the genomic DNA, indicating that the replacement was not a cloning artifact. Based on the gene structure of the allele (CYP2A6*1B), this variant was thought to be one of the causal alleles responsible for overestimation of heterozygotes for CYP2A6*4C and CYP2A6* A. To investigate this further, we developed a genotyping method which could distinguish the CYP2A6*A, CYP2A6*1B and CYP2A6*4C alleles from each other. The results clearly showed that CYP2A6*1B was the sole allele responsible for the overestimation. We conclude that the new genotyping method allows determination of six genotypes of the CYP2A6 gene, simultaneously and precisely, in both Oriental and Caucasian populations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186131     DOI: 10.1097/00008571-200011000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  9 in total

1.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

3.  Associations of CYP2A6 genotype with smoking behaviors in southern China.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Qian Zhou; Peng Ding; Yan-Hui He; Xue-Qing Yu; Wei Chen; Casey Crump; Xiao-Zhong Wen; Wei-Qing Chen
Journal:  Addiction       Date:  2011-05       Impact factor: 6.526

4.  High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.

Authors:  Maxwell Afari Gyamfi; Masaki Fujieda; Kazuma Kiyotani; Hiroshi Yamazaki; Tetsuya Kamataki
Journal:  Eur J Clin Pharmacol       Date:  2005-01-20       Impact factor: 2.953

5.  Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.

Authors:  Papichaya Phompradit; Poonuch Muhamad; Anurak Cheoymang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2014-06-02       Impact factor: 2.345

6.  Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.

Authors:  J C Mwenifumbo; C N Lessov-Schlaggar; Q Zhou; R E Krasnow; G E Swan; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

7.  Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population.

Authors:  Masanori Ohmoto; Tatsuo Takahashi; Yoko Kubota; Shinjiro Kobayashi; Yasuhide Mitsumoto
Journal:  BMC Genet       Date:  2014-12-20       Impact factor: 2.797

Review 8.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

Review 9.  Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population.

Authors:  Weixuan Zhao; Hongmei Meng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.